Speaker Profile

Ph.D., Chief Business Development Officer, Adaptive Biotechnologies

Biography
Dr. Sharon Benzeno is the Chief Business Development Officer and leads the Drug Discovery group at Adaptive. Sharon oversees the use of the company’s immune medicine platform for novel drug discovery, including TCR discovery to inform next-generation cellular therapy, antibody discovery, and vaccines. Before joining Adaptive in 2014, Sharon was Senior Director at Elsevier Inc., a healthcare informatics company. Prior to Elsevier, Sharon co-led the oncology business unit at Capgemini SE, a consulting and technology services company. Sharon came to Elsevier from Capgemini, where she held a variety of management roles at AstraZeneca plc. Sharon holds a PhD in Biomedical Sciences from New York University School of Medicine, an MBA in Finance and Leadership from New York University Stern School of Business and a BA in Biochemistry from New York University. Sharon completed a postdoctoral fellowship in cancer biology at the University of Pennsylvania Abramson Cancer Center.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chair:
Ira Mellman, Genentech

Human cells have been successfully used as treatment for blood cancers for decades but translating the promise to cell-based treatment for solid tumors has been slow. The advent of gene-editing techniques such as CRISPR, coupled with advances in our understanding of immunology and optimization of growing, manufacturing, transporting, storing, and handling specialized biological samples and materials is transforming the cell therapy field. We will hear in this session about some of the most promising work in the field, as well as the challenges in overcoming resistance

    Sessions:
  • Recent Advances in Cell-based Therapy
    Session Chair: Ira Mellman, Genentech
    - Nicholas Haining, ArsenalBio
    - Elliot Norry, Adaptimmune
    - Sarah Cooley, Fate Therapeutics
    - Liz Homans, Lyell
  • Patentability of Immunotherapies - Latest Developments
    - Janet Xiao, Morrison & Foerster LLP
  • Cell-based Therapy Challenges
    Session Chair: Lawrence Corey, Fred Hutchinson Cancer Research Center
    - Sharon Benzeno, Adaptive Biotechnologies
    - Arati Rao, PACT Pharma
    - Mark Kotter, bit.bio
  • Next-generation Supply Chain For Cell & Gene Therapies
    Session Chair: Sharon Benzeno, Adaptive Biotechnologies
    - Amy DuRoss, Vineti
    - Tim Moore, Pact Pharma
    - Teresa Foy, BMS
  • Biomarkers to Guide Immunotherapy
    Session Chair: Danny Wells, ImmunAI
    - Sanjeev Mariathasan, Genentech
    - Christine Spencer, PICI
    - Klaus Lindpaintner, InterVenn Bioscience
  • Advances in Multi-Omic Spatial Profiling
    Session Chair: Sarah Warren, NanoString Technologies
    - Chris Corless, OHSU
  • Engineered Therapeutics
    Session Chair: Daniel Chen, SITC
    - Kole Roybal, UCSF
    - Paul Parren, Lava Therapeutics